S-23: The Strongest SARM — Why It Requires Serious PCT

Meta Description: S-23 is the most potent SARM available — a full androgen receptor agonist originally developed as a male contraceptive. Learn about S-23 cycles, dosing (10-25mg/day), severe suppression, and why PCT is non-negotiable.

Most selective androgen receptor modulators were designed to be gentler than testosterone — to dissociate muscle-building activity from the prostate, scalp, and hormonal axis effects that make anabolic steroids problematic. S-23 was not. It sits at the far end of the SARM spectrum: a nonsteroidal compound that binds the androgen receptor with extraordinary affinity and behaves, in practice, far more like an oral steroid than like the mild "starter SARMs" most researchers begin with.

The reason for this is rooted in S-23's origin. It was investigated by GTx Inc. not as a physique compound but as a candidate for male hormonal contraception — a molecule whose deliberate purpose was to shut down the body's own production of sperm and testosterone (Jones et al., 2009; Chen et al., 2005). That single design intent explains nearly everything that makes S-23 both potent and demanding: the dense receptor binding, the steroid-like hardening effect, and the profound suppression that makes a structured post-cycle therapy protocol non-negotiable rather than optional.

This guide covers why S-23 has earned the "strongest SARM" label, the mechanism behind its potency, what researchers report from it, the contraceptive research angle, the reality of its suppression, dosing in a research framing, the side-effect profile, and the bloodwork and recovery scaffolding that has to surround any serious work with this compound.

Why S-23 Is Called the "Strongest SARM"

The "strongest SARM" label is not marketing shorthand. It reflects three converging pharmacological properties that separate S-23 from compounds like Ostarine, AC-262536, or even RAD-140.

The first is binding affinity. S-23 binds the androgen receptor with very high affinity — tighter than most SARMs in its class. In the preclinical work that characterized the molecule, S-23 demonstrated strong receptor occupancy and a correspondingly steep dose-response in androgen-sensitive tissue (Chen et al., 2005; Jones et al., 2009). High affinity means the compound competes aggressively for the receptor even at modest concentrations, and it stays bound long enough to drive a sustained anabolic signal.

The second is the character of that signal. Many SARMs are partial agonists — they activate the receptor only to a fraction of its maximum, which is precisely what makes them mild and recovery-friendly (the AC-262536 ceiling effect is the textbook example). S-23 is a full agonist in muscle and bone. It drives the androgen receptor toward maximal transcriptional output in those tissues, which is why the strength and hardening effects reported from it read more like a "dry" oral steroid than a typical SARM.

The third is the practical consequence: S-23 produces a more steroid-like experience top to bottom. Researchers describe rapid strength progression, pronounced muscle hardness, and a "dry" cosmetic look — but also the kind of suppression, lipid disruption, and mood effects normally associated with anabolic steroids rather than the milder SARM category. In short, S-23 buys steroid-tier results at a steroid-tier cost. The Mohler et al. (2009) and Narayanan et al. (2008) reviews of the SARM class frame this trade-off directly: tissue selectivity exists on a spectrum, and the most potent agonists sacrifice the clean separation that made SARMs attractive in the first place.

Mechanism: A Nonsteroidal Full Agonist

S-23 is a nonsteroidal selective androgen receptor modulator. "Nonsteroidal" matters: unlike testosterone or oxandrolone, S-23 is not built on the steroid backbone, which means it is not a substrate for aromatase (no conversion to estrogen) and not a substrate for 5-alpha reductase in the classical pathway. There is no estrogenic water retention and no gynecomastia mechanism intrinsic to the molecule itself.

What S-23 does share with steroids is the endpoint. It binds the androgen receptor directly, the bound receptor translocates to the cell nucleus, and it docks onto androgen response elements on DNA to drive transcription of the genes that govern muscle protein synthesis and bone density (Mohler et al., 2009). Where partial agonists recruit transcriptional coactivators incompletely and produce a submaximal response, S-23 recruits them efficiently in muscle and bone — the full-agonist behavior that defines its potency.

The tissue selectivity that justifies the "SARM" name is relative, not absolute. In preclinical models S-23 favored anabolic tissues (muscle, bone) over the prostate to a degree, and Kearbey et al. (2007) demonstrated the class effect of SARMs preventing bone loss and reducing fat mass in ovariectomized rats — a tissue-selective benefit profile. But S-23's selectivity is far less forgiving than that of milder SARMs. At the hypothalamic-pituitary level in particular, S-23 acts essentially like a potent androgen: it signals the brain hard enough to suppress the body's own hormonal cascade almost completely. That is the bridge between its mechanism and its defining liability.

Effects: Lean Mass, Hardening, and Strength

The reported effect profile of S-23 is consistent and distinctive. Across the research-user community, three outcomes dominate.

Lean mass and recomposition. As a full agonist driving maximal protein synthesis in skeletal muscle, S-23 supports lean tissue accrual that is closer to a steroid than to Ostarine. Because there is no aromatization, the weight that appears is dry tissue and glycogen — not estrogenic water. The scale moves less dramatically than on a "wet" oral like Dianabol, but the visual change can be larger relative to the weight gained.

Hardening and the "dry" look. This is the effect most associated with S-23 specifically. Users consistently describe pronounced muscle hardness, sharper separation, and increased vascularity. The absence of water retention combined with strong androgenic signaling in muscle produces a cosmetic effect that resembles Winstrol or Masteron more than a typical SARM. This makes S-23 a compound researchers gravitate toward for late-stage recomposition and conditioning work rather than bulk.

Strength. Strength progression on S-23 is reported as rapid and steroid-like. Because the compound drives near-maximal androgen receptor activation in muscle, neuromuscular output and force production climb quickly — often faster than the visible size change would suggest. This is one of the clearest experiential signals that distinguishes S-23 from partial agonists, where strength gains are gradual and modest.

These effects are real and potent. The framing that matters is that none of them are free: every property that makes S-23 effective is the same property that makes its suppression severe.

The Male-Contraceptive Research Angle

S-23's defining context is that it was studied as a male hormonal contraceptive. This is not a footnote — it is the lens through which the entire compound makes sense.

In the contraception research program (Jones et al., 2009; Chen et al., 2005), the goal was to find a compound that could maintain androgen-dependent functions (libido, muscle, mood) at the level of the receptor while shutting down the hypothalamic-pituitary-gonadal axis enough to halt spermatogenesis. S-23 did exactly that in preclinical models. By providing a strong, steady androgen signal to the hypothalamus and pituitary, it suppressed the release of gonadotropin-releasing hormone and, downstream, the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that the testes require to produce both testosterone and sperm.

The result in animal models was a reversible, near-complete suppression of fertility — sperm counts driven down sharply, with recovery after discontinuation (Jones et al., 2009). In combination work, S-23 was studied alongside estradiol to achieve fuller suppression of spermatogenesis, the contraceptive endpoint the program was pursuing.

For a researcher evaluating S-23 as a physique compound, this history is the single most important fact to internalize. The same mechanism that made it a contraceptive candidate — total suppression of FSH and LH — is operative at every dose. There is no "physique dose" that escapes the contraceptive mechanism, because the contraceptive effect and the anabolic effect are the same pharmacology pointed at two different tissues. Suppression is not a side effect of S-23; it is a primary effect.

The Reality of Heavy Suppression

Because the mechanism is designed to shut down the hormonal axis, S-23's suppression is among the most severe of any SARM. This is the central fact that governs how the compound must be approached.

Where a mild SARM like Ostarine might suppress testosterone 30-50% over a cycle, and AC-262536 might produce only 15-30% LH suppression, S-23 routinely drives LH and FSH toward the floor. Research-user bloodwork commonly shows testosterone deeply suppressed within the first weeks, with LH and FSH near the bottom of their reference ranges or below. The experience reported by users tracks this biochemistry: lethargy, low libido, flat mood, and a "shut down" feeling that emerges faster and harder than with most SARMs.

Two consequences follow directly. First, recovery is not automatic. Unlike partial agonists where many users recover without intervention, S-23's suppression is deep enough that natural recovery can be slow and incomplete, which is exactly why a SERM-based PCT is treated as mandatory rather than discretionary. Second, the duration of the cycle compounds the problem: the longer S-23 is run, the deeper the suppression entrenches, and the more recovery scaffolding the post-cycle window requires.

This is the dividing line between S-23 and the rest of the SARM category. With S-23, the question is never whether you will be suppressed — the mechanism guarantees it — but how completely you plan the recovery.

Dosing and Protocol (Research Framing)

The dosing data for S-23 comes entirely from preclinical pharmacokinetic work and community experimentation; no human clinical dosing trials have been published. GTx's preclinical pharmacokinetic data (Investigator's Brochure) established the compound's oral activity and exposure characteristics, but the figures below reflect a research framing drawn from how the compound has been used in the field, not a clinical recommendation.

S-23 is orally active with a half-life estimated in the range of 11-12 hours based on preclinical data, which is why split dosing is the common research framing — splitting the daily amount into a morning and evening portion to keep plasma concentration more stable across the day.

A few points define the protocol logic. Lower is genuinely more reasonable with S-23 than with milder SARMs, because the dose-response for suppression is steep — going from 10 mg to 25 mg does not just scale the gains, it scales the shutdown and the lipid and mood effects with it. Cycle length is deliberately shorter than the 8-12 weeks common for partial agonists; because suppression entrenches with time, most research framings cap S-23 at 6-8 weeks. And unlike compounds where PCT is optional, an S-23 protocol is incomplete on paper until the post-cycle therapy is specified alongside the on-cycle dosing.

Compared with RAD-140→ — itself a potent, suppressive SARM — S-23 is generally regarded as harder again: more hardening, more strength per milligram, and deeper suppression at equivalent perceived effect.

Side Effects: The Steroid-Tier Trade-off

S-23's side-effect profile mirrors its steroid-like potency. These are not the mild, often-negligible effects of a partial agonist; they are the effects of a strong androgen.

Severe HPTA suppression. This is the defining side effect, covered above, and the reason mandatory PCT sits at the center of any protocol. Expect deep LH/FSH and testosterone suppression, not partial.

Lipid impact. Like other potent oral androgens, S-23 can suppress HDL cholesterol and raise LDL. The cardiovascular marker shift is one of the more consistent biochemical changes researchers report and one of the primary reasons bloodwork is non-optional.

Aggression and mood. Strong androgen receptor activation in the central nervous system can sharpen aggression, irritability, and drive. Some users frame this as increased motivation; others find it volatile. It is dose-dependent and one of the experiential markers of S-23's full-agonist potency.

Hair and acne (genetic-dependent). Because S-23 is a strong androgen at the receptor, individuals genetically predisposed to androgenic alopecia or acne may see those effects accelerate. This is the same risk class as a DHT-derivative steroid: minimal for those who are not predisposed, meaningful for those who are.

Testicular and libido effects. The contraceptive mechanism shows up experientially: testicular volume can decrease on cycle and libido can fall as the axis is suppressed — the direct consequence of the FSH/LH shutdown, and one that recovers with the axis during PCT.

What S-23 does not bring is estrogenic side effects — no aromatization means no gynecomastia mechanism and no estrogenic water retention. It is also not hepatotoxic in the way C-17 alpha-alkylated orals are, since it is not methylated. The risk profile is androgenic and suppressive, not estrogenic or hepatic.

Bloodwork and PCT

Bloodwork is not advisory with S-23 — it is the only way to manage a compound whose primary effect is hormonal shutdown.

A pre-cycle baseline should capture total and free testosterone, LH, FSH, a full lipid panel, and a complete blood count, so that the depth of suppression and the lipid shift can be measured against a real starting point rather than guessed at. A mid-cycle lipid panel is worthwhile given S-23's HDL impact. The most important panel, however, is the post-PCT one: repeating testosterone, LH, and FSH four or more weeks after PCT ends is the only way to confirm the axis has actually recovered rather than assuming it.

Because S-23's suppression is deep, the post-cycle therapy is built around a SERM — typically Nolvadex→ (tamoxifen), often with Clomid→ (clomiphene) for stronger LH/FSH stimulation when the suppression warrants it. The SERM blocks estrogenic negative feedback at the hypothalamus and pituitary, releasing the brake on LH and FSH so the testes restart endogenous testosterone production. A representative research framing runs Nolvadex at 20-40 mg/day (often tapered) for four weeks, with Clomid added where recovery is sluggish — but the protocol should be calibrated to the measured depth of suppression, not run blind.

For the full mechanics of SERM selection, dosing, timing, and HCG considerations, see the PCT Hub and the SARMs PCT Guide. The principle that governs all of it: with S-23, PCT is part of the cycle, not an afterthought to it.

Frequently Asked Questions

Is S-23 really stronger than RAD-140?

By most measures researchers care about — receptor binding affinity, hardening effect, and degree of suppression — yes. S-23 is generally regarded as the most potent SARM, behaving closer to an oral steroid than to a typical SARM. RAD-140 is potent and suppressive in its own right, but S-23 is the more aggressive compound on both the benefit and the cost side. The greater hardening and strength come with deeper, harder-to-recover-from suppression.

Do I really need PCT after S-23?

Yes — unconditionally. This is the single non-negotiable rule with S-23. Because the compound was designed to suppress the hormonal axis (it was studied as a male contraceptive), it drives LH and FSH toward the floor and testosterone with them. Natural recovery from that depth of suppression is slow and unreliable without a SERM-based PCT. Running S-23 without planning PCT first is the most common and most consequential mistake with this compound.

Will S-23 affect fertility?

In its original research context, S-23 suppressed spermatogenesis — that was the entire point of the contraceptive program (Jones et al., 2009). On cycle, sperm production and testicular function are suppressed alongside the axis. In animal models the effect was reversible on discontinuation, and human research-user recovery tracks the return of the axis during PCT, but anyone for whom fertility is a near-term concern should weigh this mechanism heavily.

Does S-23 cause gyno or water retention?

No, not through an estrogenic mechanism. S-23 is nonsteroidal and does not aromatize, so there is no estrogen conversion driving gynecomastia or water retention. The look it produces is dry and hard rather than bloated. The trade-off is that the risks it does carry — suppression, lipid shifts, aggression, androgenic hair/acne effects — are the androgenic ones, which are harder to manage than estrogen with an AI.

How long should an S-23 cycle run?

Shorter than most SARM cycles. Because suppression deepens the longer the compound is run, common research framings cap S-23 at 6-8 weeks rather than the 8-12 weeks typical for milder SARMs. Longer cycles do not meaningfully improve the risk-to-reward ratio — they mostly deepen the recovery problem.

Conclusion

S-23 is the SARM that broke the SARM premise. The category was built on dissociation — muscle without the hormonal cost — and S-23 deliberately reunites them, because it was engineered for the opposite goal: to suppress the hormonal axis as a male contraceptive. That origin is the key to the whole compound. Its high binding affinity, full-agonist hardening and strength, and steroid-tier suppression are not separate facts; they are one pharmacology seen from different angles.

For a researcher, that means S-23 should be approached with the seriousness of an oral steroid, not the casualness of a starter SARM. The results — dry mass, sharp conditioning, fast strength — are real and among the strongest in the SARM space. But they are bought with the deepest suppression in the category, and the only responsible way to work with that is to plan the bloodwork and the SERM-based PCT before the first dose, not after. With S-23, the recovery protocol is not the cleanup; it is half the cycle.

Nova Pharma carries third-party tested S-23 and PCT support compounds with full purity documentation for Canadian researchers.

S-23→ Nolvadex→ Clomid→ Post-Cycle Therapy Hub

References:

1. Jones A, et al. Nonsteroidal selective androgen receptor modulators as male hormonal contraceptives. J Clin Endocrinol Metab. 2009;94(10):4442-4448. PMID: 19789204
2. Chen J, et al. A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther. 2005;312(2):546-553. PMID: 15356213
3. Narayanan R, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010. PMID: 18612376
4. Mohler ML, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597-3617. PMID: 19432422
5. Kearbey JD, et al. Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24(2):328-335. PMID: 17063395
6. GTx Inc. Preclinical pharmacokinetic data, S-23. Investigator's Brochure.

This article is for educational purposes only and does not constitute medical advice. Consult a healthcare professional before using any research compound.